Quick Facts

• Primary Therapeutic Domain: Ophthalmic relief for minor eye irritation.
• Targeted Symptoms: Temporary relief of ocular redness, burning, and irritation.
• Associated Conditions: Symptoms related to allergic reactions, exposure to environmental factors like dust or wind, and minor conjunctival irritation.

---

Окуметил (Ocumetyl), an ophthalmic solution, is an available option for the temporary management of minor eye irritations. Its primary therapeutic applications are focused on providing symptomatic relief for the eye.

Main Uses and Benefits

This medication is indicated for the temporary relief of symptoms associated with minor conjunctival irritation. It is typically used to address ocular discomfort such as temporary relief of burning and general eye irritation that may be due to factors like dryness, wind, dust, or exposure to minor allergens. Additionally, the solution may help manage visible eye redness by promoting a temporary reduction in blood vessel visibility on the eye's surface.

Its use is intended to support the reduction of irritation associated with common environmental or allergic triggers.

This medicine is approved for use in adults who do not have documented contraindications. Eligibility for Окуметил (Diphenhydramine, Naphazoline, Zinc sulfate ophthalmic solution) is strictly defined by regulatory guidelines to prevent use in certain populations where risks are established or not fully evaluated.

Absolute Contraindications

Use is formally contraindicated in patients with:

• Known narrow-angle glaucoma.
• Hypersensitivity to any component (Diphenhydramine, Naphazoline, or Zinc sulfate).
• Concurrent use of, or use within 14 days of, Monoamine Oxidase Inhibitors (MAOIs).
• Neonates, infants, and nursing mothers.

---

Age-Specific and Conditional Restrictions

Age-Related Eligibility: The medicine is not recommended for children under 6 years of age. Use in older children and adolescents may be classified as not well established, and it is contraindicated in infants.

Conditional Use: Use with Caution is required for patients with pre-existing cardiovascular issues, including hypertension and heart disease. This caution also applies to patients with metabolic conditions such as diabetes mellitus and hyperthyroidism, as well as those with prostatic hypertrophy.

Pregnancy Status: Use during pregnancy is restricted and permitted only when the potential benefit is clearly documented to outweigh the potential risk.

The official interaction profile of Окуметил, an ophthalmic solution, is derived from the known systemic potential of its active components, Diphenhydramine and Naphazoline, as documented in regulatory information.

Official Interaction Statements

• Contraindicated Combinations and Timing Restriction: The most stringent regulatory restriction involves Monoamine Oxidase Inhibitors (MAOIs), which are classified as a contraindicated combination due to the sympathomimetic activity of Naphazoline and the risk of a severe hypertensive crisis. A timing separation rule, typically requiring a two-week washout period after MAOI discontinuation, is mandatory.
• Pharmacodynamic Potentiation: The antihistamine component (Diphenhydramine) causes pharmacodynamic potentiation when combined with Alcohol and various Central Nervous System (CNS) Depressants (e.g., tranquillizers, hypnotics), intensifying sedation. The effects of other Anticholinergic Drugs may also be potentiated.
• Metabolic Interaction (CYP2D6): Diphenhydramine is a documented CYP2D6 inhibitor. This pharmacokinetic interaction may result in increased systemic exposure and reduced clearance for co-administered CYP2D6 substrates, such as metoprolol or venlafaxine.

These established constraints structure the product’s official interaction profile. The regulatory documents define these patterns to manage risks associated with altered clearance and enhanced sedative or pressor effects.

The drug’s activity results from the coordinated pharmacodynamic actions of three components, targeting alpha-adrenergic receptors, H1 receptors, and superficial proteins.

Vascular Tone Modulation (Alpha-Adrenergic Agonism)

Naphazoline acts as a direct alpha-adrenergic agonist, stimulating alpha-receptors on the smooth muscle of conjunctival arterioles. This interaction initiates a signaling cascade that results in vasoconstriction, physically reducing the local volume of blood in the tissue as a consequence of arteriolar contraction.

---

Modulation of Histamine Signaling ( H1 Receptor Blockade)

The activity of Diphenhydramine is achieved through competitive H1-antagonism. By binding to the H1 receptors, the drug blocks the physiological effects of the endogenous inflammatory mediator histamine, preventing its action on capillary endothelium. This action maintains the integrity of the capillary walls and limits fluid extravasation, minimizing the physiological consequence of tissue fluid accumulation.

---

Surface Integrity Adjustment (Astringent Action)

The third mechanism is mediated by Zinc sulfate, which exerts a local astringent effect via non-receptor-mediated interaction with superficial tissue proteins. This protein precipitation strengthens the immediate surface layers, which reduces local exudation and fluid release, contributing to altered surface integrity.

Окуметил is formulated as an ophthalmic solution intended solely for topical ocular administration, meaning it is applied directly to the surface of the eye. The medication follows a standardized administration regimen for this drug class.

The standard application volume involves the instillation of one or two drops into the affected eye(s) per application. This application may be repeated up to a maximum frequency of four times daily (QID), establishing the upper limit for the treatment schedule.

Usage is strictly designated for short-term, temporary relief. Continuous use must not exceed 72 hours (three days). If relief is not achieved or symptoms persist beyond this duration, the application should cease.

For proper use, several procedural conditions are established: patients are instructed to remove contact lenses prior to instillation to prevent interaction with the preservative, and care must be taken to avoid contact between the container tip and any surface to maintain the solution's sterility. Regarding pediatric use, for children under 6 years of age, administration guidance must be sought from a health professional. This entire protocol defines a specific pattern of intermittent, short-term use.

Research Evidence / Overview of Studies for Окуметил

Evidence for Symptom Relief in Non-Specific Eye Irritation

Research examining this solution was evaluated in studies exploring minor eye discomfort associated with non-allergic factors. This research uses the framework provided by regulatory documentation for its components, specifically the decongestant Naphazoline and the astringent Zinc Sulfate. Studies were applied in research contexts involving fluctuating symptoms, such as burning sensation and general eye irritation caused by environmental factors.

Studies monitored objective outcomes related to physical discomfort, such as changes in visible ocular redness (hyperemia). Studies monitored the relationship between use and changes in patient-reported scores for irritation. Research provides insight into short-term changes, but there is limited information for long-term outcomes, as this usage is relevant to short-term, acute episodes.

Evidence for Symptom Relief in Allergic Ocular Irritation

The evidence base for its use in exploring symptoms related to allergic ocular irritation focuses on the established research for Antihistamine/Decongestant combinations. Research examined patient-reported outcomes describing perceived discomfort, particularly the core allergic outcome of ocular itching (pruritus). Studies also monitored outcomes capturing phases of heightened symptom activity, such as changes in conjunctival swelling and redness.

Similar Randomized Controlled Trials (RCTs) involving analogous fixed-dose combinations have explored short-term symptom changes, where data showed patterns related to patient-reported scores for allergic discomfort. Evidence so far indicates that the presence of the antihistamine component is relevant in trials assessing short-term allergic symptom patterns.

What Remains Uncertain About the Research Base for Окуметил

Research highlights what is known and what is still uncertain regarding the combination of active ingredients. A major gap is the lack of head-to-head research evaluating the role in clinical practice of the triple fixed-dose combination (Diphenhydramine, Naphazoline, and Zinc Sulfate) compared to the individual components or two-component alternatives. Comparative evidence is lacking, which means the unique contribution of each ingredient to the observed outcomes is difficult to fully assess. Furthermore, the follow-up durations were limited across the existing studies, meaning long-term effects are not fully established.

Key Studies & References NIH DailyMed: General Guidance on Professional Drug Labeling and Monographs (Basis for Fixed-Dose Combination Regulatory Context)

Common questions about Окуметил (FAQ)

Q: Can Окуметил be used to treat bacterial conjunctivitis?

A: According to the official product information, Окуметил is indicated for the treatment of chronic non-specific conjunctivitis and irritations of the anterior segment of the eye, as well as angular conjunctivitis. The official product literature does not list bacterial conjunctivitis as a specific indication for Окуметил.

Q: How does zinc sulfate in the formula help the eye?

A: Official information states that the zinc sulfate component in Окуметил provides local antiseptic and astringent effects. Antiseptic means it helps inhibit the growth of certain microorganisms, while astringent effects can help reduce inflammation and irritation in the eye tissues.

Q: Does Окуметил help with redness from eye irritation?

A: Regulatory documents indicate that Окуметил is indicated for addressing redness and swelling (edema) in the anterior segment of the eye, which is commonly associated with various irritations. This action is primarily attributed to the active components that constrict blood vessels and help reduce inflammation.

Q: Can Окуметил be used for swelling of the eyelids?

A: The official documentation lists swelling (edema) of the conjunctiva as an indication for Окуметил. While it addresses swelling in the eye area, the official indication focuses on swelling of the conjunctiva and the anterior segment of the eyeball, not specifically the eyelids.

Q: What is the role of diphenhydramine in the product?

A: Official product information notes that diphenhydramine, one of the active ingredients in Окуметил, acts as a histamine H1-receptor blocker. This mechanism is associated with an antiallergic effect, which may help to reduce symptoms like itching and irritation related to allergic reactions in the eye.

Q: Are there specific eye conditions that Окуметил is not recommended for?

A: Yes, official sources list several conditions where Окуметил is contraindicated (not recommended). These include specific types of glaucoma, dry eye syndrome (keratoconjunctivitis sicca), and certain other severe eye diseases. The full set of contraindications is detailed in the official product information.

Q: Can Окуметил be used to relieve eye strain from long screen use?

A: The official indications for Окуметил are chronic non-specific conjunctivitis and irritation of the anterior segment of the eye. It is not explicitly labeled for treating visual fatigue or eye strain caused by screen use. Its intended use is for conditions tied to inflammation and irritation of the eye's outer surface.

Q: Does the product contain a preservative?

A: Yes, according to the official product composition, Окуметил contains benzalkonium chloride. This substance is included to serve as a preservative, maintaining the sterility and stability of the eye drop solution.

Q: Can children use Окуметил?

A: The official product literature indicates that the use of Окуметил is contraindicated (not recommended) for children under the age of two years, according to the official regulatory information.

How to Store and Dispose of Окуметил?

Regulatory documents specify strict conditions for storing and disposing of Окуметил ophthalmic solution to ensure product stability and safety.

Mandatory Storage Requirements

The solution must be stored at room temperature, specifically between 15 C and 25 C. The container must be kept tightly closed in a location that is protected from light. It is a mandatory child-safety rule to keep the medicine out of the sight and reach of children.

Stability Constraint	Condition
Unopened Shelf-Life	3 years
Post-Opening Use Period	1 month

Disposal Instructions

Once the product is expired or no longer needed, it must be disposed of in accordance with local regulatory requirements for pharmaceutical waste. The solution should not be disposed of in household waste or wastewater.